Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
COVID-19
Biotech
Moderna touts 3 phase 1 data sets to bolster early vax work
Early-stage shots aimed at Epstein–Barr virus, norovirus and shingles could further solidify the biotech's infectious disease portfolio.
Max Bayer
Mar 27, 2024 3:21pm
Moderna's next-gen COVID vax surpasses approved version in ph. 3
Mar 26, 2024 10:55am
Mendaera picks up Avail Medsystems' COVID-era virtual OR assets
Mar 19, 2024 11:26am
Siemens Healthineers to close down Fast Track PCR testing unit
Mar 19, 2024 10:02am
Moderna won't advance US-backed Zika vaccine without more money
Mar 15, 2024 11:10am
Protease inhibitor outperforms Paxlovid protecting lungs of mice
Mar 14, 2024 6:30am
More News
Layoffs at Meissa Vaccines as biotech's future lies in limbo
Mar 5, 2024 10:25am
Gritstone lays off 40% of team after delaying COVID vax trial
Feb 29, 2024 4:05pm
CytoDyn finally clears FDA hold on HIV program after 2 years
Feb 29, 2024 10:20am
Investors home in on Moderna's RSV, CMV prospects
Feb 22, 2024 10:09am
See more stories